Payment overview · 2025
General Payments
$781.53
48 reported records · 14 companies
Healthcare provider profile · identity verified
Sean Koch, MD
Allopathic & Osteopathic Physicians|Family Medicine · WYNNE, AR · NPI 1184112112
Verified facts
What the public records show
CMS Open Payments records show Sean Koch, MD received $781.53 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.96 | 37.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.48 | 26.3% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.94 | 7.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.98 | 5.2% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $34.70 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.69 | 3.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.20 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.12 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.28 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.25 | 1.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.36 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.02 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.87 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $781.53 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $197.56 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.84 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.84 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.28 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.36 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.69 | 2 | 2025 |
Source payment records
|
|||||
| Miro 3D Normalized: miro 3d |
Device | Reprise Biomedical, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.16 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $12.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 144 |
| Gabapentin | Gabapentin | 288 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 263 | 86 |
| Losartan Potassium | Losartan Potassium | 258 | 89 |
| Omeprazole | Omeprazole | 215 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 56 |
| Mounjaro | Tirzepatide | 183 | 34 |
| Alprazolam | Alprazolam | 175 | 42 |
| Tramadol Hcl | Tramadol Hcl | 170 | 50 |
| Trazodone Hcl | Trazodone Hcl | 166 | 60 |
| Ozempic | Semaglutide | 158 | 33 |
| Lisinopril | Lisinopril | 148 | 59 |
| Furosemide | Furosemide | 146 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 139 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 47 |
| Meloxicam | Meloxicam | 135 | 52 |
| Metformin Hcl | Metformin Hcl | 129 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 46 |
| Potassium Chloride | Potassium Chloride | 110 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 35 |
| Allopurinol | Allopurinol | 103 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 37 |
| Spironolactone | Spironolactone | 83 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 37 |
| Eliquis | Apixaban | 79 | 22 |
| Clonazepam | Clonazepam | 78 | 15 |
| Glipizide Er | Glipizide | 78 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 21 |
| Jardiance | Empagliflozin | 77 | 27 |
| Simvastatin | Simvastatin | 77 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 23 |
| Carvedilol | Carvedilol | 71 | 32 |
| Donepezil Hcl | Donepezil Hcl | 71 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 35 |
| Lorazepam | Lorazepam | 69 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 28 |
| Pregabalin | Pregabalin | 68 | 27 |
| Bupropion Xl | Bupropion Hcl | 66 | 27 |
| Montelukast Sodium | Montelukast Sodium | 64 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 21 |
| Celecoxib | Celecoxib | 58 | 15 |
| Famotidine | Famotidine | 58 | 20 |
| Farxiga | Dapagliflozin Propanediol | 57 | 11 |
| Sertraline Hcl | Sertraline Hcl | 57 | 30 |
| Ezetimibe | Ezetimibe | 56 | 22 |
| Metformin Hcl Er | Metformin Hcl | 56 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Atenolol | Atenolol | 51 | 16 |
| Glimepiride | Glimepiride | 50 | 14 |
| Fluconazole | Fluconazole | 48 | 24 |
| Prednisone | Prednisone | 48 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 21 |
| Linzess | Linaclotide | 46 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 14 |
| Promethazine Hcl | Promethazine Hcl | 43 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Methylprednisolone | Methylprednisolone | 39 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 15 |
| Buspirone Hcl | Buspirone Hcl | 37 | 17 |
| Azithromycin | Azithromycin | 35 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Ondansetron Odt | Ondansetron | 34 | 23 |
| Diazepam | Diazepam | 33 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 12 |
| Primidone | Primidone | 32 | suppressed |
| Topiramate | Topiramate | 32 | 15 |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 19 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 12 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Verapamil Er Pm | Verapamil Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $781.53 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, FARXIGA, Kerendia, LINZESS, MINIMED 780G, Miro 3D, Miro3D, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error